This study provides a novel intervention strategy for overcoming immunotherapy resistance in microsatellite stable colorectal cancer, suggesting that combining PIK3CA inhibitors with PD-1 blockade may reshape the tumor immune microenvironment, inspiring the design of future combination therapies.
Literature Overview
The article titled “Copanlisib in combination with nivolumab for microsatellite stable colorectal cancer: a phase 1/2 trial”, published in Nature Communications, systematically investigates the clinical potential of combining PIK3CA pathway inhibition with anti–PD-1 immune checkpoint blockade in microsatellite stable (MSS) colorectal cancer (CRC). Through a prospective phase I/II trial design, the study evaluates the safety, efficacy, and pharmacodynamic biomarkers of copanlisib (a PI3K inhibitor) combined with nivolumab (an anti–PD-1 antibody) in patients with metastatic MSS CRC who have failed multiple prior lines of therapy. The study not only validates previously proposed resistance mechanisms from preclinical models but also reveals features of therapy-induced remodeling of the immune microenvironment through multi-omics dynamic monitoring.Background Knowledge
Colorectal cancer is the second leading cause of cancer-related deaths worldwide, with approximately 95% of metastatic cases being microsatellite stable (MSS) or mismatch repair–proficient (MMRp). These patients show minimal response to single-agent immune checkpoint inhibitors (ICIs) such as PD-1 blockers, representing a major unmet clinical need. Although PIK3CA mutations occur in about 15% of MSS CRC cases and are associated with immune escape, monotherapy with PI3K inhibitors or their combination with chemotherapy has shown limited efficacy. Current third-line regimens such as regorafenib or famitinib yield a median progression-free survival (PFS) of only 1.9–5.6 months and an objective response rate (ORR) below 6%, highlighting the urgent need for novel therapeutic strategies. Based on prior findings that PIK3CA mutations can mediate resistance to anti–PD-1 therapy, the research team hypothesized that targeting the PI3K pathway might reverse the immunosuppressive tumor microenvironment. This pathway promotes tumor cell survival via AKT/mTOR signaling and activates PI3Kγ in myeloid-derived suppressor cells (MDSCs), contributing to immunosuppression. Thus, targeting PIK3CA offers a precise approach to simultaneously inhibit intrinsic tumor signaling and improve the immune microenvironment, providing a strategic entry point to overcome immunotherapy resistance in MSS CRC.
Research Methods and Experiments
The study employed an open-label, multicenter phase I/II design, enrolling 39 patients with metastatic MSS CRC who had progressed after at least two prior lines of therapy, divided into PIK3CA wild-type (n=17) and mutant (n=22) cohorts. The treatment regimen consisted of copanlisib (60 mg on days 1, 8, and 15) plus nivolumab (480 mg on day 1), administered in 28-day cycles. The primary endpoint was objective response rate (ORR) at 6 months; secondary endpoints included PFS, OS, duration of response (DoR), and disease control rate (DCR). The study prospectively collected tumor biopsies and peripheral blood samples at baseline and during treatment (around week 6) for multi-omics analyses. Tumor microenvironment (TME) spatial profiling was performed using Orion and CyCIF multiplex immunofluorescence, combined with CyTOF mass cytometry to analyze peripheral immune cell phenotypes, enabling systematic assessment of treatment-induced immune infiltration. Additionally, dynamic monitoring of signaling pathways using phosphoprotein markers (e.g., pAKT, pERK, pS6) revealed pharmacodynamic changes.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides the first clinical evidence for precision immunotherapy in PIK3CA-mutant MSS CRC, demonstrating that targeting the PI3K pathway can partially overcome the immune-desert phenotype. Although ORR is modest, the durable responses highlight a significantly benefiting subgroup, emphasizing the importance of biomarker-driven patient selection. The observed TME remodeling and feedback signaling mechanisms provide a theoretical foundation for optimizing combination strategies, such as adding MAPK pathway inhibitors or targeting myeloid cells. Furthermore, the phenomenon of delayed responses suggests that efficacy assessment periods should be extended to avoid prematurely discontinuing potentially effective treatments.
Conclusion
This study marks a significant step forward in addressing immunotherapy-resistant solid tumors, specifically microsatellite stable colorectal cancer (MSS CRC). By combining the PIK3CA inhibitor copanlisib with the anti–PD-1 antibody nivolumab, the research not only validates the clinical targetability of PIK3CA mutations in mediating immunotherapy resistance but also reveals their dual role in reshaping the immune microenvironment. Despite limited overall response rates, a subset of patients achieved over two years of progression-free survival, underscoring the importance of precise patient selection. Multi-omics analyses identified baseline CD8+ T cell and CD163+ macrophage infiltration as predictive of response, while treatment-induced T cell infiltration coexists with feedback activation of the MAPK pathway, indicating the need for combination strategies. These findings provide critical guidance for future clinical trial designs: focusing on patients with PIK3CA pathway alterations, extending follow-up durations, and exploring triplet therapies to block compensatory signaling. Bridging the gap from bench to bedside, this study establishes a complete framework from mechanistic exploration to biomarker validation, laying the foundation for improving outcomes in MSS CRC and advancing personalized combination immunotherapy.
